熱門資訊> 正文

XTL生物制药宣布1比4 ADS比例变更

2026-03-21 04:19

Xtl生物製藥(XTLB) 0

XTL Biopharmaceuticals (XTLB) will change its ADS ratio from 1:100 to 1:400 effective March 25, 2026.
The move is equivalent to a 1-for-4 reverse ADS split for shareholders.
No fractional ADSs will be issued; proceeds from fractional sales will be distributed in cash.

More on XTL Biopharmaceuticals

XTL announces receipt of staff delisting letter from Nasdaq
Financial information for XTL Biopharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。